Manufacturing News of Note—AveXis goes deeper on Zolgensma manufacturing; 76B opioid pills manufactured

stocks
According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. (Pixabay)

Here is some news of note for the week: 

> Catalent Biologics and Novartis’ company AveXis have struck a long-term deal in which the biotech will have dedicated manufacturing space at a Catalent facility for the production of AveXis' Zolgensma, its newly approved gene therapy for spinal muscular atrophy. Release 

> Data recently released as part of a civil action show that U.S. drugmakers manufactured 76 billion oxycodone and hydrocodone pills from 2006 through 2012 as the opioid epidemic spread. Story

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. Release

 


 

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.